Pharmacokinetics and pharmacodynamics in critically ill patients

Current Opinion in Anaesthesiology

Volumn 23, Issue 4, 2010, Pages 472-478

  Varghese, Julie M ^a   Roberts, Jason A ^a,b   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

antibiotics; continuous infusion; dosing; renal replacement therapy; target site

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ATORVASTATIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFALOTIN; CEFEPIME; CEFOTAXIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; CYTOCHROME P450 3A4; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; LINEZOLID; MEROPENEM; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; PIPERACILLIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN; VORICONAZOLE; ANTIINFECTIVE AGENT; DRUG;

ANTIBIOTIC THERAPY; ANURIA; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; BOLUS INJECTION; BRAIN INJURY; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG TOXICITY; EXTENDED DAILY DIALYSIS; EXTRACORPOREAL OXYGENATION; HOSPITAL INFECTION; HUMAN; KIDNEY INJURY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PATHOPHYSIOLOGY; PERITONEAL FLUID; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; SINGLE DRUG DOSE; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; CRITICAL ILLNESS; METABOLISM; PHARMACOKINETICS;

ANIMALS; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL REPLACEMENT THERAPY;

EID: 77954657561     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328339ef0a     Document Type: Review

References (39)

1. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-851.
2. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49:1-16.
3. Vincent J-L, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. J Am Med Assoc 2009; 302:2323-2329.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
5. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081.
6. van Zanten ARH, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23:422-430.
7. Lipman J, Scribante J, Gous AGS, et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998; 42:2235-2239.
8. Conil J-M, Georges B, de Lussy A, et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents 2008; 32:505-510.
9. Patanwala AE, Norris CJ, Nix DE, et al. Vancomycin dosing for pneumonia in critically ill trauma patients. J Trauma 2009; 67:802-804.
10. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009; 53:1863-1867.
11. Martin JH, Fay MF, Udy A, et al. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J (in press). doi: 10.1111/j.1445-5994.2009.02160.x.
12. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 149:443-448.
13. Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30:674-681.
14. Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47:1298-1304.
15. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001; 33:161-235.
16. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-3436.
17. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42:1411-1423.
18. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008; 31:122-129.
19. Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53:1476-1481.
20. Roberts JA, Kirkpatrick CMJ, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64:142-150.
21. Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis: bolus versus continuous administration? Crit Care Med 2009; 37:926-933.
22. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of [beta]-lactam antibiotics. Crit Care Med 2009; 37:2071-2078.
23. Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37:2268-2282.
24. Li AMMY, Gomersall CD, Choi G, et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 2009; 64:929-937.
25. Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24:267-271.
26. Kielstein JT, Eugbers C, Bode-Boeger SM, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2009 [Epub ahead of print]. doi:10.1093/ndt/gfp704.
27. Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2009 [Epub ahead of print]. doi: 10.1007/s00228-009-0766-9.
28. Mushatt DM, Mihm LB, Dreisbach AW, Simon EE. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009; 49:433-437.
29. Mehta NM, Halwick DR, Dodson BL, et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 2007; 33:1018-1024.
30. Spriet I, Annaert P, Meersseman P, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 2009; 63:767-770.
31. Ruiz S, Papy E, Da Silva D, et al. Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med 2009; 35:183-184.
32. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993; (Supp D):1-16.
33. Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009; 53:4907-4910.
34. Seguin P, Verdier MC, Chanavaz C, et al. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. J Antimicrob Chemother 2009; 63:564-567.
35. Dalley AJ, Lipman J, Deans R, et al. Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers. Antimicrob Agents Chemother 2009; 53:210-215.
36. Roberts DJ, Goralski KB, Renton KW, et al. Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain. Crit Care Med 2009; 37:2767-2774.
37. The STATInS trial: Statins in Sepsis Study 2007 ACTRN 12607000028404. [cited 1 March 2010]. Available from: http://www.anzctr.org.au/trial-view. aspx?ID=81692.
38. The CAS trial: Continued use of Atorvastatin in sepsis 2006 ACTRN12605000756628. [cited 1 March 2010]. Available from: http:// www.anzctr.org.au/trial-view.aspx?ID=886.
39. Kruger PS, Freir NM, Venkatesh B, et al. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009; 35:717-721.